Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00356681
Status:
TERMINATED
Last Update Posted:
2015-10-15
First Post:
2006-07-24
Brief Title:
A Study of AMG 706 or Bevacizumab in Combination With Paclitaxel Chemotherapy as Treatment for Breast Cancer
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Randomized Phase 2 Trial of Double-Blind Placebo Controlled AMG 706 in Combination With Paclitaxel or Open-Label Bevacizumab in Combination With Paclitaxel as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer
Status:
TERMINATED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision to close study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CIRGTORI 010 | None | None | None |